Are DAWN and TALK Obtaining Fair Deals for their Shareholders? Accessibility Statement Skip NavigationInsiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket paym ...

Core Insights - Day One Biopharmaceuticals (DAWN) has entered into a definitive agreement with Servier for the acquisition of all outstanding shares at $21.50 each, valuing the deal at approximately $2.5 billion [1][7] Group 1: Acquisition Details - The acquisition will enable Servier to add Ojemda, DAWN's first marketed drug, which received accelerated FDA approval in 2024 for treating relapsed or refractory pediatric low-grade glioma (pLGG) [2] - The deal is expected to close in the second quarter, with Servier planning to finance the transaction through existing cash and investments [3] Group 2: Financial Performance - Following the acquisition announcement, DAWN's stock price surged nearly 66%, and the stock has increased by 127% year-to-date compared to the industry's 4% growth [4] Group 3: Strategic Rationale - Servier's interest in DAWN aligns with its 2030 goal to develop innovative treatments across various therapeutic areas, including oncology [6] - Ojemda reported sales of $155.4 million for the full year 2025, reflecting a 172% year-over-year increase, with projected sales for 2026 estimated between $225 million and $250 million [6] Group 4: Portfolio Expansion - In addition to Ojemda, the acquisition will enhance Servier's oncology portfolio with two early-stage antibody drug conjugate (ADC) candidates, emiltatug ledadotin (emi-le) and DAY301, which are currently in separate early-stage studies [8] - This acquisition is part of Servier's broader strategy, which includes previous deals in the oncology space, such as licensing agreements with Black Diamond Therapeutics and Ideaya Biosciences [9]

Core Viewpoint - Day One Biopharmaceuticals Inc. is experiencing significant investor interest following its announcement of being acquired by Servier for $2.5 billion, resulting in a 100% increase in its stock price week-on-week, with a tender offer reflecting a 68% premium over its previous closing price [1][3]. Group 1: Acquisition Details - Day One Biopharmaceuticals will be acquired by France-based Servier, with all outstanding shares being tendered at $21.50 each, representing a 68% upside from the prior closing price of $12.78 [3]. - The transaction is expected to close in the second quarter of the year, pending customary closing conditions, including shareholder approval [3]. Group 2: Strategic Fit and Future Outlook - The CEO of Day One Biopharmaceuticals emphasized that Servier's successful track record in rare cancers and commitment to targeted therapies aligns with Day One's mission to provide medicines for patients with life-threatening diseases [4]. - The acquisition is seen as an opportunity to enhance the reach of Day One's scientific advancements, particularly in pediatric low-grade glioma, while maintaining a patient-first approach [5].

Core Viewpoint - Day One Biopharmaceuticals Inc. is set to merge with France-based Servier for $2.5 billion, leading to a significant increase in its stock price, marking it as a stock to watch [1][2]. Group 1: Merger Details - Day One Biopharmaceuticals and Servier have entered into a definitive agreement for the acquisition, with Servier set to acquire shares at $21.50 each, representing a 68% increase from Day One's latest closing price [2]. - Following the announcement, Day One's shares peaked at $21.23 during intra-day trading, ultimately closing up by 65.88% at $21.20 [4]. Group 2: Strategic Implications - The merger is expected to close in the second quarter of the year, pending customary closing conditions [4]. - Day One's CEO, Jeremy Bender, emphasized that Servier's expertise in rare cancers and commitment to targeted therapies aligns with Day One's mission to provide medicines for patients with life-threatening diseases [4]. - Bender also noted that joining Servier offers an opportunity to enhance the reach of their science, particularly in pediatric low-grade glioma, while maintaining a patient-first approach [5].

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Day One Biopharmaceuticals, Inc. to Servier, focusing on the adequacy of the sale price of $21.50 per share and the process leading to this valuation [1]. Group 1: Proposed Sale Details - The proposed transaction involves Day One Biopharmaceuticals, Inc. shareholders receiving $21.50 in cash for each share they own [1]. - KSF is assessing whether the proposed consideration adequately reflects the company's value or if it undervalues the company [1]. Group 2: Legal Rights and Contact Information - Shareholders who believe the transaction undervalues the company can discuss their legal rights with KSF without obligation or cost [1]. - Interested parties can contact KSF Managing Partner Lewis S. Kahn via email or phone for more information [1].

Core Viewpoint - The law firm Brodsky & Smith is investigating potential claims against the Board of Directors of Day One Biopharmaceuticals, Inc. for possible breaches of fiduciary duty related to the company's sale to Servier for $21.50 per share, totaling approximately $2.5 billion [1][2]. Group 1 - The investigation focuses on whether the Day One Board failed to conduct a fair process and whether the sale price provides fair value to shareholders [2]. - The transaction is an all-cash deal valued at approximately $2.5 billion, with each share priced at $21.50 [1]. - Brodsky & Smith has a history of representing shareholders in securities and class action lawsuits, recovering millions for clients [3].

Core Viewpoint - Ademi LLP is investigating Day One Biopharmaceuticals, Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Servier, which involves a cash payment of $21.50 per share, totaling approximately $2.5 billion in equity value [1] Group 1: Transaction Details - Day One stockholders will receive $21.50 per share in cash, amounting to a total equity value of around $2.5 billion [1] - The transaction agreement includes provisions that significantly limit competing offers for Day One, imposing a substantial penalty if a competing bid is accepted [1] Group 2: Investigation Focus - The investigation by Ademi LLP centers on the conduct of Day One's board of directors and whether they are meeting their fiduciary responsibilities to all shareholders [1] - Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual shareholder rights [1]

Core Viewpoint - Day One Biopharmaceuticals (NASDAQ: DAWN) shares have surged 65% following Servier's agreement to acquire the company for $2.5 billion, but further upside is unlikely as the stock is already trading close to the buyout price [1][1]. Group 1: Acquisition Details - Servier's acquisition values DAWN shares at $21.5 each, indicating a nearly 70% upside from the previous close [1][1]. - The deal provides immediate liquidity and mitigates commercialization risks associated with independent biotech firms [1][1]. - The acquisition positions Day One within a global oncology framework, enhancing its credibility with regulators and institutional investors [1][1]. Group 2: Market Implications - The stock is currently trading at approximately $21.50, suggesting that the market has priced in most of the deal's value [1][1]. - Analysts believe that unless a bidding war occurs, which is deemed unlikely, there is no fundamental reason for further price increases [1][1]. - The acquisition marks a significant milestone for the biotech sector, indicating continued demand for high-quality oncology assets [1][1]. Group 3: Future Outlook - For current DAWN shareholders, the recent price jump is a reward for enduring previous volatility [1][1]. - The risk-reward ratio for new investors has shifted unfavorably, with the deal premium already reflected in the current price [1][1]. - The transaction highlights that strategic buyers are willing to pay premiums for differentiated oncology assets, reinforcing confidence in the biotech sector despite market volatility [1][1].

Core Viewpoint - Monteverde & Associates PC is investigating Day One Biopharmaceuticals, Inc. regarding its proposed sale to Servier Pharmaceuticals LLC, where shareholders are expected to receive $21.50 in cash per share, raising questions about the fairness of the deal [1]. Group 1 - The investigation is led by class action attorney Juan Monteverde, who has a successful track record in recovering millions for shareholders [1]. - The proposed transaction involves Day One shareholders receiving $21.50 per share, prompting scrutiny over whether this is a fair deal [1]. - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report, indicating its credibility in handling such cases [1].

Core Viewpoint - Servier will acquire Day One Biopharmaceuticals for approximately $2.5 billion, enhancing its cancer treatment pipeline [1] Group 1: Acquisition Details - The acquisition price is set at $21.50 per share, representing a 68% premium over Day One's closing price prior to the announcement [1] - The deal includes Day One's Ojemda, the only drug in its class for treating low-grade glioma in children aged six months and older [1] - The transaction is expected to close in the second quarter of the year [1] Group 2: Strategic Implications - Olivier Laureau, Servier's president, emphasized that the acquisition strengthens Servier's position as a global leader in rare oncology [1] - The acquisition aligns with Servier's long-term commitment to invest in science addressing significant unmet medical needs [1] - The deal is part of Servier's 2030 ambition to accelerate innovation for patients with rare cancers [1] Group 3: Market Reaction - Following the announcement, Day One's stock surged nearly 66% after trading resumed [1] - Day One's shares were trading around $21.19 in premarket trades after the news [1] - The stock's relative strength line reached a new high prior to the acquisition announcement [1]